Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers

Collin M. Blakely, Thomas B.K. Watkins, Wei Wu, Beatrice Gini, Jacob J. Chabon, Caroline E. McCoach, Nicholas McGranahan, Gareth A. Wilson, Nicolai J. Birkbak, Victor R. Olivas, Julia Rotow, Ashley Maynard, Victoria Wang, Matthew A. Gubens, Kimberly C. Banks, Richard B. Lanman, Aleah F. Caulin, John St John, Anibal R. Cordero, Petros GiannikopoulosAndrew D. Simmons, Philip Mack, David R Gandara, Hatim Husain, Robert C. Doebele, Jonathan Riess, Maximilian Diehn, Charles Swanton, Trever G. Bivona

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

A widespread approach to modern cancer therapy is to identify a single oncogenic driver gene and target its mutant-protein product (for example, EGFR-inhibitor treatment in EGFR-mutant lung cancers). However, genetically driven resistance to targeted therapy limits patient survival. Through genomic analysis of 1,122 EGFR-mutant lung cancer cell-free DNA samples and whole-exome analysis of seven longitudinally collected tumor samples from a patient with EGFR-mutant lung cancer, we identified critical co-occurring oncogenic events present in most advanced-stage EGFR-mutant lung cancers. We defined new pathways limiting EGFR-inhibitor response, including WNT/β-catenin alterations and cell-cycle-gene (CDK4 and CDK6) mutations. Tumor genomic complexity increases with EGFR-inhibitor treatment, and co-occurring alterations in CTNNB1 and PIK3CA exhibit nonredundant functions that cooperatively promote tumor metastasis or limit EGFR-inhibitor response. This study calls for revisiting the prevailing single-gene driver-oncogene view and links clinical outcomes to co-occurring genetic alterations in patients with advanced-stage EGFR-mutant lung cancer.

Original languageEnglish (US)
Pages (from-to)1693-1704
Number of pages12
JournalNature Genetics
Volume49
Issue number12
DOIs
StatePublished - Dec 1 2017

Fingerprint

Lung Neoplasms
Neoplasms
Exome
cdc Genes
Catenins
Mutant Proteins
Therapeutics
Oncogenes
Genes
Neoplasm Metastasis
Mutation
Survival
DNA

ASJC Scopus subject areas

  • Genetics

Cite this

Blakely, C. M., Watkins, T. B. K., Wu, W., Gini, B., Chabon, J. J., McCoach, C. E., ... Bivona, T. G. (2017). Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nature Genetics, 49(12), 1693-1704. https://doi.org/10.1038/ng.3990

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. / Blakely, Collin M.; Watkins, Thomas B.K.; Wu, Wei; Gini, Beatrice; Chabon, Jacob J.; McCoach, Caroline E.; McGranahan, Nicholas; Wilson, Gareth A.; Birkbak, Nicolai J.; Olivas, Victor R.; Rotow, Julia; Maynard, Ashley; Wang, Victoria; Gubens, Matthew A.; Banks, Kimberly C.; Lanman, Richard B.; Caulin, Aleah F.; St John, John; Cordero, Anibal R.; Giannikopoulos, Petros; Simmons, Andrew D.; Mack, Philip; Gandara, David R; Husain, Hatim; Doebele, Robert C.; Riess, Jonathan; Diehn, Maximilian; Swanton, Charles; Bivona, Trever G.

In: Nature Genetics, Vol. 49, No. 12, 01.12.2017, p. 1693-1704.

Research output: Contribution to journalArticle

Blakely, CM, Watkins, TBK, Wu, W, Gini, B, Chabon, JJ, McCoach, CE, McGranahan, N, Wilson, GA, Birkbak, NJ, Olivas, VR, Rotow, J, Maynard, A, Wang, V, Gubens, MA, Banks, KC, Lanman, RB, Caulin, AF, St John, J, Cordero, AR, Giannikopoulos, P, Simmons, AD, Mack, P, Gandara, DR, Husain, H, Doebele, RC, Riess, J, Diehn, M, Swanton, C & Bivona, TG 2017, 'Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers', Nature Genetics, vol. 49, no. 12, pp. 1693-1704. https://doi.org/10.1038/ng.3990
Blakely, Collin M. ; Watkins, Thomas B.K. ; Wu, Wei ; Gini, Beatrice ; Chabon, Jacob J. ; McCoach, Caroline E. ; McGranahan, Nicholas ; Wilson, Gareth A. ; Birkbak, Nicolai J. ; Olivas, Victor R. ; Rotow, Julia ; Maynard, Ashley ; Wang, Victoria ; Gubens, Matthew A. ; Banks, Kimberly C. ; Lanman, Richard B. ; Caulin, Aleah F. ; St John, John ; Cordero, Anibal R. ; Giannikopoulos, Petros ; Simmons, Andrew D. ; Mack, Philip ; Gandara, David R ; Husain, Hatim ; Doebele, Robert C. ; Riess, Jonathan ; Diehn, Maximilian ; Swanton, Charles ; Bivona, Trever G. / Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. In: Nature Genetics. 2017 ; Vol. 49, No. 12. pp. 1693-1704.
@article{380a4a5dfee44d01877969e3a593d015,
title = "Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers",
abstract = "A widespread approach to modern cancer therapy is to identify a single oncogenic driver gene and target its mutant-protein product (for example, EGFR-inhibitor treatment in EGFR-mutant lung cancers). However, genetically driven resistance to targeted therapy limits patient survival. Through genomic analysis of 1,122 EGFR-mutant lung cancer cell-free DNA samples and whole-exome analysis of seven longitudinally collected tumor samples from a patient with EGFR-mutant lung cancer, we identified critical co-occurring oncogenic events present in most advanced-stage EGFR-mutant lung cancers. We defined new pathways limiting EGFR-inhibitor response, including WNT/β-catenin alterations and cell-cycle-gene (CDK4 and CDK6) mutations. Tumor genomic complexity increases with EGFR-inhibitor treatment, and co-occurring alterations in CTNNB1 and PIK3CA exhibit nonredundant functions that cooperatively promote tumor metastasis or limit EGFR-inhibitor response. This study calls for revisiting the prevailing single-gene driver-oncogene view and links clinical outcomes to co-occurring genetic alterations in patients with advanced-stage EGFR-mutant lung cancer.",
author = "Blakely, {Collin M.} and Watkins, {Thomas B.K.} and Wei Wu and Beatrice Gini and Chabon, {Jacob J.} and McCoach, {Caroline E.} and Nicholas McGranahan and Wilson, {Gareth A.} and Birkbak, {Nicolai J.} and Olivas, {Victor R.} and Julia Rotow and Ashley Maynard and Victoria Wang and Gubens, {Matthew A.} and Banks, {Kimberly C.} and Lanman, {Richard B.} and Caulin, {Aleah F.} and {St John}, John and Cordero, {Anibal R.} and Petros Giannikopoulos and Simmons, {Andrew D.} and Philip Mack and Gandara, {David R} and Hatim Husain and Doebele, {Robert C.} and Jonathan Riess and Maximilian Diehn and Charles Swanton and Bivona, {Trever G.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/ng.3990",
language = "English (US)",
volume = "49",
pages = "1693--1704",
journal = "Nature Genetics",
issn = "1061-4036",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers

AU - Blakely, Collin M.

AU - Watkins, Thomas B.K.

AU - Wu, Wei

AU - Gini, Beatrice

AU - Chabon, Jacob J.

AU - McCoach, Caroline E.

AU - McGranahan, Nicholas

AU - Wilson, Gareth A.

AU - Birkbak, Nicolai J.

AU - Olivas, Victor R.

AU - Rotow, Julia

AU - Maynard, Ashley

AU - Wang, Victoria

AU - Gubens, Matthew A.

AU - Banks, Kimberly C.

AU - Lanman, Richard B.

AU - Caulin, Aleah F.

AU - St John, John

AU - Cordero, Anibal R.

AU - Giannikopoulos, Petros

AU - Simmons, Andrew D.

AU - Mack, Philip

AU - Gandara, David R

AU - Husain, Hatim

AU - Doebele, Robert C.

AU - Riess, Jonathan

AU - Diehn, Maximilian

AU - Swanton, Charles

AU - Bivona, Trever G.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - A widespread approach to modern cancer therapy is to identify a single oncogenic driver gene and target its mutant-protein product (for example, EGFR-inhibitor treatment in EGFR-mutant lung cancers). However, genetically driven resistance to targeted therapy limits patient survival. Through genomic analysis of 1,122 EGFR-mutant lung cancer cell-free DNA samples and whole-exome analysis of seven longitudinally collected tumor samples from a patient with EGFR-mutant lung cancer, we identified critical co-occurring oncogenic events present in most advanced-stage EGFR-mutant lung cancers. We defined new pathways limiting EGFR-inhibitor response, including WNT/β-catenin alterations and cell-cycle-gene (CDK4 and CDK6) mutations. Tumor genomic complexity increases with EGFR-inhibitor treatment, and co-occurring alterations in CTNNB1 and PIK3CA exhibit nonredundant functions that cooperatively promote tumor metastasis or limit EGFR-inhibitor response. This study calls for revisiting the prevailing single-gene driver-oncogene view and links clinical outcomes to co-occurring genetic alterations in patients with advanced-stage EGFR-mutant lung cancer.

AB - A widespread approach to modern cancer therapy is to identify a single oncogenic driver gene and target its mutant-protein product (for example, EGFR-inhibitor treatment in EGFR-mutant lung cancers). However, genetically driven resistance to targeted therapy limits patient survival. Through genomic analysis of 1,122 EGFR-mutant lung cancer cell-free DNA samples and whole-exome analysis of seven longitudinally collected tumor samples from a patient with EGFR-mutant lung cancer, we identified critical co-occurring oncogenic events present in most advanced-stage EGFR-mutant lung cancers. We defined new pathways limiting EGFR-inhibitor response, including WNT/β-catenin alterations and cell-cycle-gene (CDK4 and CDK6) mutations. Tumor genomic complexity increases with EGFR-inhibitor treatment, and co-occurring alterations in CTNNB1 and PIK3CA exhibit nonredundant functions that cooperatively promote tumor metastasis or limit EGFR-inhibitor response. This study calls for revisiting the prevailing single-gene driver-oncogene view and links clinical outcomes to co-occurring genetic alterations in patients with advanced-stage EGFR-mutant lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=85035788250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035788250&partnerID=8YFLogxK

U2 - 10.1038/ng.3990

DO - 10.1038/ng.3990

M3 - Article

C2 - 29106415

AN - SCOPUS:85035788250

VL - 49

SP - 1693

EP - 1704

JO - Nature Genetics

JF - Nature Genetics

SN - 1061-4036

IS - 12

ER -